Opinion|Videos|June 26, 2024
Payer Coverage Considerations for New Treatments for Alzheimer Disease
Experts discuss how payers can prepare for new treatments and plan adequate coverage for patients with Alzheimer disease.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How can plan sponsors effectively prepare for these new treatments and plan coverage in a way that ensure adequate care for patients with Alzheimer disease and availability of coverage for all patients?
Advertisement
Related to this article
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
3
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5